BR112022026747A2 - Métodos de tratamento do distúrbio do espectro da neuromielite óptica - Google Patents

Métodos de tratamento do distúrbio do espectro da neuromielite óptica

Info

Publication number
BR112022026747A2
BR112022026747A2 BR112022026747A BR112022026747A BR112022026747A2 BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2 BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A BR112022026747 A BR 112022026747A BR 112022026747 A2 BR112022026747 A2 BR 112022026747A2
Authority
BR
Brazil
Prior art keywords
methods
treatment
nmosd
spectrum disorders
neuromyelitis
Prior art date
Application number
BR112022026747A
Other languages
English (en)
Portuguese (pt)
Inventor
Rees William
Katz Eliezer
Smith Michael
Mittereder Nanette
Original Assignee
Viela Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viela Bio Inc filed Critical Viela Bio Inc
Publication of BR112022026747A2 publication Critical patent/BR112022026747A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
BR112022026747A 2020-06-30 2021-06-30 Métodos de tratamento do distúrbio do espectro da neuromielite óptica BR112022026747A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063046133P 2020-06-30 2020-06-30
US202063052093P 2020-07-15 2020-07-15
US202063071092P 2020-08-27 2020-08-27
PCT/US2021/039911 WO2022006283A2 (en) 2020-06-30 2021-06-30 Methods of treating neuromyelitis optica spectrum disorder

Publications (1)

Publication Number Publication Date
BR112022026747A2 true BR112022026747A2 (pt) 2023-01-24

Family

ID=79321915

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022026747A BR112022026747A2 (pt) 2020-06-30 2021-06-30 Métodos de tratamento do distúrbio do espectro da neuromielite óptica

Country Status (11)

Country Link
US (1) US20230406928A1 (https=)
EP (1) EP4172211A4 (https=)
JP (1) JP2023534916A (https=)
KR (1) KR20230030642A (https=)
CN (1) CN116234571A (https=)
AU (1) AU2021299307A1 (https=)
BR (1) BR112022026747A2 (https=)
CA (1) CA3178954A1 (https=)
IL (1) IL299381A (https=)
MX (1) MX2022016236A (https=)
WO (1) WO2022006283A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021368769A1 (en) * 2020-10-29 2023-06-08 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease
CN117797245A (zh) * 2023-12-29 2024-04-02 广州赛莱拉干细胞科技股份有限公司 人乳脂球表皮生长因子8用于制备治疗视神经脊髓炎谱系疾病药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020263418A1 (en) * 2019-04-24 2021-11-11 Viela Bio, Inc. Use of an anti-CD19 antibody to treat autoimmune disease
AU2021368769A1 (en) * 2020-10-29 2023-06-08 Viela Bio, Inc. Use of an anti-cd19 antibody to treat autoimmune disease

Also Published As

Publication number Publication date
US20230406928A1 (en) 2023-12-21
MX2022016236A (es) 2023-03-29
CN116234571A (zh) 2023-06-06
EP4172211A4 (en) 2024-07-10
JP2023534916A (ja) 2023-08-15
EP4172211A2 (en) 2023-05-03
WO2022006283A3 (en) 2022-02-03
AU2021299307A1 (en) 2022-12-22
KR20230030642A (ko) 2023-03-06
CA3178954A1 (en) 2022-01-06
WO2022006283A2 (en) 2022-01-06
IL299381A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112022026747A2 (pt) Métodos de tratamento do distúrbio do espectro da neuromielite óptica
BR112022006781A2 (pt) Anticorpos modificados como degradadores moleculares através de receptores celulares
BRPI0515884A (pt) métodos de diagnóstico e tratamento de complicações da gravidez
BRPI0507442B8 (pt) método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
BR112013000027A2 (pt) tratamento de distúrbios cognitivos
BRPI0910993A2 (pt) técnica de administração na linha de sutura usando toxinas botulínicas
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
BR112017005110A2 (pt) anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença.
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
BR112023019427A2 (pt) Sistema e método para determinar um cronograma de tratamento
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
Koike et al. Application of functional near infrared spectroscopy as supplementary examination for diagnosis of clinical stages of psychosis spectrum
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
BR112021024634A2 (pt) Método de tratamento ou prevenção de um distúrbio, doença ou condição aliviada pela estimulação ou modulação da expressão de colágeno
BR112021021141A2 (pt) Método para modular estrutura glicocalyx endotelial
BR112022026999A2 (pt) Anticorpos anti-il-36r para tratamento de dermatoses neutrofílicas
BR112022023928A2 (pt) Uso de canabidiol para o tratamento do transtorno do espectro autista
BR112022008886A2 (pt) Diagnóstico de transtornos de humor usando biomarcadores de edição de rna do sangue
BR112022015387A2 (pt) Proteínas actriib variantes e usos das mesmas
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
Kalotra et al. 5‐Nonyloxytryptamine oxalate–embedded collagen–laminin scaffolds augment functional recovery after spinal cord injury in mice
Simhadri et al. Dysregulation of LIMK‐1/cofilin‐1 pathway: a possible basis for alteration of neuronal morphology in experimental cerebral malaria
BR112023023558A2 (pt) Anticorpos anti-tmprss6 e usos dos mesmos
Suto et al. Rat model of attention-deficit hyperactivity disorder exhibits delayed recovery from acute incisional pain due to impaired descending noradrenergic inhibition

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: VIELA BIO, INC. (US)